Stage 3 Cancer Life Expectancy
Understanding the odds of survival is a good starting point for treating cancer, because once you understand the odds you can resolve to beat them 2. Cancer progression is divided into stages, with later stages being more difficult to treat and cure. Stage three cancer is one step away from the final stage (stage four) and has a lower survival rate and shorter overall life expectancy than stage two 2.
Cancer
Cancer is a malignant growth of cells where the body fails to properly dispose of mutant or abnormal cells. As cancer cells divide at a rate faster than normal cells, over time they will come to dominate the organism, resulting in termination of life as vital functions are irreparably compromised. Symptoms include weight loss, feelings of general unease, night sweats and chills.
- Cancer is a malignant growth of cells where the body fails to properly dispose of mutant or abnormal cells.
- As cancer cells divide at a rate faster than normal cells, over time they will come to dominate the organism, resulting in termination of life as vital functions are irreparably compromised.
Cancer Stages
About Esophageal Cancer Life Expectancy
Learn More
According to the National Cancer Institute, cancer progression is divided into five separate stages, with each indicating roughly how far the tumor has spread throughout your system 1. In stage zero, the tumor is still confined to the original site. In stage one and two, the tumor has grown or begun to expand into deeper layers of the original tissue. In stage three, the tumor has begun to spread outward to surrounding areas and some lymph nodes, but it has yet to metastasize. In stage four, the tumor has metastasized--spread throughout the body to sites far away from the original location.
- According to the National Cancer Institute, cancer progression is divided into five separate stages, with each indicating roughly how far the tumor has spread throughout your system 1.
- In stage one and two, the tumor has grown or begun to expand into deeper layers of the original tissue.
Stage Three Survival Rate
The general five-year survival rate for stage three cancer depends on the type of cancer with which you are infected 2. For example, according to EMedTV.com, the survival rate for stage three lung cancer is 15.5 percent, whereas the survival rate for stage three colon cancer is around 64 percent 2. These figures represent the average percentage of patients who will be alive five years after the date of their diagnosis.
Life Expectancy
Life Expectancy for Spinal & Brain Cancer
Learn More
Like survival rates, life expectancy for stage three cancer can vary widely depending on the particular type of cancer with which you are infected 2. Additionally, according to lungdiseasefocus.com, determining life expectancy is difficult for anything less than stage four cancers, because there is still a possibility that the cancer can be pushed into remission. Thus, it is impossible to determine life expectancy except on a case-by-case basis.
Considerations
Even if your doctor has provided you with a less than favorable life expectancy, remember that at best it is just an educated guess based on statistics from individuals with similar cases. Thus, it is entirely likely that you will be able to exceed any life expectancy estimate by a substantial margin. A positive attitude is key in fighting cancer, so keep your head held high throughout to maximize your life expectancy with any stage of cancer.
Related Articles
References
- National Cancer Institute
- Cancer Survival Statistics
- Kay FU, Kandathil A, Batra K, Saboo SS, Abbara S, Rajiah P. Revisions to the Tumor, Node, Metastasis staging of lung cancer (8 edition): Rationale, radiologic findings and clinical implications. World J Radiol. 2017;9(6):269-79. doi:10.4329/wjr.v9.i6.269
- National Cancer Institute. Cancer staging. Updated March 9, 2015.
- National Cancer Institute. AJCC stage groupings and TNM definitions. In: Non-Small Cell Lung Cancer Treatment (PDQ)–Health Professional Version. Updated May 7, 2020.
- National Institutes of Health. Lung and bronchus cancer SEER 5-year relative survival rates, 2010-2016 by stage at diagnosis and age, both sexes, all races (includes Hispanic). 2020.
- De Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220-33. doi:10.21037/tlcr.2018.05.06
- Hong H, Wang Q, Li J, Liu H, Meng X, Zhang H. Aging, cancer and immunity. J Cancer. 2019;10(13):3021-7. doi:10.7150/jca.30723
- Jassem J. Tobacco smoking after diagnosis of cancer: Clinical aspects. Transl Lung Cancer Res. 2019;8(Suppl 1):S50-8. doi:10.21037/tlcr.2019.04.01
- Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. J Thorac Dis. 2012;4(5):474-84. doi:10.3978/j.issn.2072-1439.2012.05.11
- Pinto JA, Vallejos CS, Raez LE, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. ESMO Open. 2018;3(3):e000344. doi:10.1136/esmoopen-2018-000344
- Cancer Research UK. Lung cancer survival statistics: One-, five-, and 10-year survival for lung cancer. 2019.
- Cetin K, Ettinger DS, Hei YJ, O'Malley CD. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol. 2011;3:139-48. doi:10.2147/CLEP.S17191
- Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288-300. doi:10.21037/tlcr.2016.06.07
- Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943-53. doi:10.2147/CMAR.S187317
- Urvay SE, Yucel B, Erdis E, Turan N. Prognostic factors in stage III non-small-cell lung cancer patients. Asian Pac J Cancer Prev. 2016;17(10):4693-7. doi:10.22034/APJCP.2016.17.10.4693
- Islam KM, Jiang X, Anggondowati T, Lin G, Ganti AK. Comorbidity and survival in lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2015;24(7):1079-85. doi:10.1158/1055-9965.EPI-15-0036
- Sasaki H, Suzuki A, Tatematsu T, et al. Prognosis of recurrent non-small cell lung cancer following complete resection. Oncol Lett. 2014;7(4):1300-4. doi:10.3892/ol.2014.1861
- Koshy M, Fedewa SA, Malik R, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013;8(7):915-22. doi:10.1097/JTO.0b013e31828f68b4
Writer Bio
TS Jordan is an Ohio licensed attorney living and practicing out of the Cleveland area. In addition to his Juris Doctorate, he holds a Bachelors' Degree in Information Systems. He has been writing professionally for less than a year.